8-K: Armata Pharmaceuticals Appoints New CFO, Adjusts Executive Contracts

Armata Pharmaceuticals announced the promotion of David House to Chief Financial Officer and updated employment terms for Pierre Kyme, effective July 17, 2026.

Summary

• David House has been promoted to Chief Financial Officer (CFO) of Armata Pharmaceuticals, Inc., effective July 17, 2026.
• House previously served as Senior Vice President, Finance and principal financial officer since August 2024.
• His new role includes an annual base salary of $371,315.
• He is eligible for a target annual bonus of 50% of his base salary.
• He is also eligible for annual equity awards with a current intended grant date fair value of approximately $300,000, commencing in 2026.
• The company also amended Pierre Kyme's employment agreement to align the definition of 'change in control' with that of other senior executives.
• The amendment to Kyme's agreement, dated June 1, 2024, was effective July 17, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily detailing routine executive appointments and contract adjustments without significant new financial performance data or strategic shifts.

Positives

• Promotion of David House to CFO, recognizing internal talent.
• Clear compensation structure for the new CFO, including base salary, bonus potential, and equity awards.
• Alignment of executive contract terms regarding 'change in control' for consistency across senior management.

Risks

• Potential for involuntary termination without Cause or resignation for Good Reason for David House, which would trigger 12 months of base salary severance.
• Vesting acceleration of equity awards for David House if an involuntary termination occurs within one month prior to or 12 months following a Change in Control.
• Potential for Pierre Kyme's equity awards to accelerate if an involuntary termination occurs within one month prior to or 12 months following a Change in Control.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it details compensation and severance terms for key executives, which are standard components of employment agreements.

Management Comments

• David House will serve as Chief Financial Officer, reporting directly to the Chief Executive Officer.
• The annual target performance bonus percentage for David House is subject to increase, but not decrease, from time to time in the discretion of the Board or the compensation committee.
• The current intent of the compensation committee is to provide David House with an equity award each fiscal year, commencing in 2026, with a grant date fair value of approximately $300,000.

Industry Context

StockSavvy.ai notes that executive appointments and compensation adjustments are common events in the pharmaceutical industry, particularly for companies undergoing growth or strategic realignments. Ensuring clear contractual terms and alignment with governance standards is crucial for investor confidence.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of a CFO and adjustments to executive contracts are standard corporate actions that maintain operational continuity and governance. The compensation details provide transparency.
• Employees: The promotion of David House may signal internal growth opportunities. The alignment of 'change in control' clauses ensures consistent treatment for senior executives in such events.
• Management: Clearer contractual terms and defined roles for key executives.

Next Steps

• David House will assume duties as Chief Financial Officer.
• The company will continue to adhere to the terms of the amended employment agreements for David House and Pierre Kyme.
• Equity awards for David House will commence in fiscal year 2026, subject to Board/Committee discretion.

Key Dates

Keywords

Armata Pharmaceuticals, CFO Appointment, David House, Executive Compensation, Employment Agreement, Change in Control, Pierre Kyme, Form 8-K